Researchers demonstrated that nanopore sequencing of plasma cell‑free DNA (cfDNA) from critically ill patients can concurrently detect pathogen sequences and tissue‑of‑origin signals from the same blood sample. The study showed feasibility for rapid, minimally invasive diagnostics that combine infectious‑disease detection with host‑response and tissue injury signatures. Authors argue the approach could accelerate pathogen ID and precision triage in intensive‑care settings, though further validation and clinical workflow integration are required before routine use.